RECENT PLACEMENT

Occam Places Biotech Leader David Southwell as Chairman of Revolo Biotherapeutics

Occam Places Biotech Leader David Southwell as Chairman of Revolo Biotherapeutics

In January 2024, Occam recruited serial biotech CEO David Southwell as Chairman of Revolo Biotherapeutics, a Morningside investment with a novel platform addressing autoimmune disorders.

David is an experienced financial executive who earlier in his career worked in numerous private and public companies and executed multiple IPOs. He subsequently migrated to operational leadership roles with small biotechs and larger commercial-stage companies.


Most recently, David served as CEO of TScan Therapeutics, Inc. (NASDAQ: TCRX), a clinical-stage immuno-oncology company focused on T cell receptors.  Prior to that, he was the CEO of Inotek Pharmaceuticals (NASDAQ: ITEK), a clinical-stage ophthalmology company that merged with Rocket Pharmaceuticals in 2018.  David also served as the EVP and CFO of Human Genome Sciences until that company was acquired by GSK in 2012, and then as EVP and CFO of Sepracor.  His career began in investment banking at Lehman Brothers Inc.

‍

Recent Placements

  1. Bastiano Sanna as CEO of Semma
  2. Bill Brondyk as CSO at Invetx
  3. Aron Feingold as VP of Investor Relations & Corporate Communications at Geron
  4. Brian Goldman as Chief Computation Officer at ZebiAI
  5. Ann Taylor as Board Member at Comanche Biopharma
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.